Skip to main content Skip to section navigation Skip to footer
  • About
    • Discover Mineralys
    • Purpose & Values
    • Our Team
  • Science
    • Lorundrostat
    • Aldosterone
    • Hypertension
    • Cardio-Renal-Metabolic Syndrome
  • Pipeline
  • Investors
  • Publications
  • Contact Us
    • Careers & Culture
    • Partnering
    • Contact Form
Menu
  • About
    • Discover Mineralys
    • Purpose & Values
    • Our Team
  • Science
    • Lorundrostat
    • Aldosterone
    • Hypertension
    • Cardio-Renal-Metabolic Syndrome
  • Pipeline
  • Investors
  • Publications
  • Contact Us
    • Careers & Culture
    • Partnering
    • Contact Form

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • SEC Filings
    • All SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Nov 09, 2023 4:05 pm EST

Mineralys Therapeutics to Participate in Three Upcoming Conferences

Nov 07, 2023 4:05 pm EST

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 02, 2023 10:00 am EDT

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Oct 31, 2023 4:05 pm EDT

Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

Oct 13, 2023 4:10 pm EDT

Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

Sep 14, 2023 4:05 pm EDT

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Sep 11, 2023 4:05 pm EDT

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

Sep 10, 2023 7:47 am EDT

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Sep 10, 2023 7:45 am EDT

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

Sep 05, 2023 4:05 pm EDT

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Mineralys Therapeutics, LLC
  • Terms & Conditions
  • Privacy Policy
  • X/Twitter Icon Twitter
  • Linkedin